Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Exercise program aims to fight diabetes and muscle decline in older adults

NCT ID NCT07398495

Symptom relief Sponsor: yueh chu wu Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a 12-week multimodal exercise program—combining supervised training, home exercises, and digital support—can improve muscle function, physical performance, and blood sugar control in adults aged 45 to 85 with both type 2 diabetes and sarcopenia (age-related muscle loss). Researchers will measure changes in muscle strength, walking speed, and HbA1c levels. The goal is to find a practical, non-drug approach to help this population stay stronger and healthier.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Multimodal Exercise Program
What this could lead to
If it works, this could point toward a simple, drug-free way to help older adults with diabetes maintain muscle strength and better control their blood sugar.
What could go wrong
This is a small, early-stage behavioral study with no blinding or placebo, so results may be modest or not generalizable. Participants must be able to exercise safely.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 128 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with both Type 2 Diabetes Mellitus (T2DM) and sarcopenia. * Maintained on a stable regimen of oral hypoglycemic agents. * Aged 45 years or older. * Capable of communicating effectively in Mandarin or Taiwanese. * Willing to provide informed consent or have it obtained from a legally authorized representative. Exclusion Criteria: * • Limited limb or joint function that prevents exercise (e.g., recent fractures or dislocations). * Communication barriers or severe emotional/psychological issues (e.g., uncontrolled depression or severe mental illness). * Severe cognitive impairment (e.g., dementia). * End-stage renal disease (ESRD). * Major comorbidities or complications, including active diabetic foot ulcers, amputation, recent myocardial infarction, severe autonomic neuropathy, or a history of stroke within the last 3 years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sarcopenia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Sarcopenia type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sarcopenia Type 2 diabetes mellitus (T2DM)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chung Shan Medical University Hospital

    RECRUITING

    Taichung, Taiwan, 402306, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.